Lv4
488 积分 2025-10-08 加入
Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management
6小时前
待确认
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
16天前
已完结
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
16天前
已完结
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
19天前
已完结
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
22天前
已完结
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
22天前
已完结
FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid
29天前
已完结
PPARs in liver physiology
30天前
已完结
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
30天前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease
5个月前
已完结
皖公网安备34019202002308
